Spanish generics manufacturer selects TraceLink for serialisation compliance

The first generics pharmaceutical manufacturer in Spain, Norman Laboratories, has selected TraceLink’s serialisation solutions to meet the forthcoming EU Falsified Medicines Directive (FMD) requirements.

“At Normon, we uphold our commitment to developing the safest and highest quality medicines at affordable prices for everyone. Our dedication to ensuring patient safety was a key factor in selecting a partner with a proven solution to comply with the EU FMD,” explained Gonzalo Fernández Govantes, chief operating officer of Normon Laboratories. “We selected TraceLink for its demonstrated EU and country compliance capabilities and enterprise scalability. As Normon continues to expand its business through ongoing innovation, we are confident that TraceLink can provide the breadth of support needed in order for Normon to successfully comply with EU and global regulations.”

“We are pleased to be working with Normon Laboratories, a pioneer in the development of generic medications, and one of the leading pharmaceutical companies in Spain. At TraceLink, we understand and value the need to implement an EU FMD compliance strategy that can scale quickly to accommodate for rapid growth and impending deadlines for serialization and individual country compliance,” said Shabbir Dahod, president and CEO of TraceLink. “Drug traceability and serialisation is a global initiative and we look forward to working closely with Normon Laboratories to meet the approaching EU FMD deadline for serialisation and ultimately, help secure the integrity of its products for patients across Europe.”

Norman Laboratories supplies products to multiple markets, shipping high volumes of pharmaceuticals throughout Spain and exported to global locations. Additionally, it offers contract manufacturing capabilities for customers.